JPMorgan on Kyverna Therapeutics Inc (KYTX): 'armed with compelling clinical evidence to-date'
Tweet Send to a Friend
JPMorgan analyst Brian Cheng reiterated an Overweight rating and $33.00 price target on Kyverna Therapeutics Inc (NASDAQ: KYTX).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
